Volume 11.24 | Jul 3

Prostate Cell News 11.24 | Jul 3
Prostate Cell News by STEMCELL Technologies
Vol. 11.24 – 3 July, 2020
TOP STORY

The Landscape of RNA Polymerase II-Associated Chromatin Interactions in Prostate Cancer

Scientists mapped the RNA polymerase II-associated chromatin interactions in normal prostate cells and prostate cancer cells.
[Journal of Clinical Investigation]

Full Article

Watch 'collaborating to accelerate COVID-19 research'
PUBLICATIONSRanked by the impact factor of the journal

Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-Mediated Signaling Cascade

The authors investigated the effect of exogenous chemerin on human prostate and sarcoma tumor lines. Key signaling pathway components were elucidated using qPCR, Western blotting, siRNA knockdown, and specific inhibitors.
[Clinical Cancer Research]

Abstract

Targeting the KDM4B-AR-c-Myc Axis Promotes Sensitivity to Androgen Receptor Targeted Therapy in Advanced Prostate Cancer

Scientists found that KDM4B was overexpressed in enzalutamide-resistant prostate cancer cells. Overexpression of KDM4B promoted recruitment of androgen receptor to the c-Myc gene enhancer and induced H3K9 demethylation.
[Journal of Pathology]

Abstract

Validation of the Four-miRNA Biomarker Panel MiCaP for Prediction of Long-Term Prostate Cancer Outcome

Functional effects of the four MiCaP miRNAs were assessed by overexpression and inhibition experiments in prostate cancer cell lines.
[Scientific Reports]

Full Article

Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9

Researchers report a novel synthetic lethal interaction between inhibitors of O-GlcNAc transferase and CDK9 that specifically killed prostate cancer cells but not normal cells.
[Molecular Cancer Research]

Abstract

Modulating Tumor Reactive Stroma by Extracorporeal Shock Waves to Control Prostate Cancer Progression

Two different stabilized cell lines of androgen-resistant prostate cancer were treated with the conditioned media produced by extracorporeal shock waves-treated carcinoma-associated fibroblasts.
[Prostate]

Abstract

Cediranib, an Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Inhibits Proliferation and Invasion of Prostate Adenocarcinoma Cells

Investigators determined the anti-neoplastic activity of Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in the metastatic castration-resistant prostate cancer cell lines.
[European Journal of Pharmacology]

Abstract

The Combined Antibacterial and Anticancer Properties of Nano Ce-Containing Mg-Phosphate Ceramic

Cell viability test was performed for the ceramics on Vero cells, and their antitumor activity was determined by a PC3 cell line.
[Life Sciences]

Abstract

Recapitulation of Prostate Tissue Cell Type-Specific Transcriptomes by an In Vivo Primary Prostate Tissue Xenograft Model

Endothelial cells and epithelial cells were isolated from seven fresh human prostate tissue specimens and from primary tissue xenografts established from nine fresh human prostate tissue specimens.
[PLoS One]

Full Article

Prostate Cancer Cells Modulate the Differentiation of THP-1 Cells in Response to Etoposide and TLR Agonists Treatments

To imitate the relationship between cancer cells and tumor-associated macrophages, investigators co-cultured macrophages with etoposide-treated PC3 cells.
[Cell Biology International]

Abstract

Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
REVIEWS

Cecropins in Cancer Therapies-Where We Have Been?

The authors present publications demonstrating cytolytic properties against tumor cells of members belonging to the cecropin family, as well as synthesized cecropin B with the introduced modification of its sequence and conjugated cecropin B with a modified luteinizing hormone-releasing hormone.
[European Journal of Pharmacology]

Full Article

INDUSTRY AND POLICY NEWS

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer

Ipsen announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials.
[Ipsen Pharma]

Press Release

Hong Kong Universities Rattled by New Security Law

Academics in Hong Kong are facing new worries after the mainland government abruptly imposed a controversial new security law that critics say could infringe on human rights and chill academic freedom.
[ScienceInsider]

Editorial

United Kingdom Plans ‘Office for Talent’ to Smooth Entry for Top Scientists

The UK government plans to set up an “office for talent” to oversee visas and make it easier to attract top scientists after Brexit, according to an R&D road map.
[ScienceInsider]

Editorial

FEATURED EVENT

Life Science Innovation Northwest Conference

July 16 – July 17
Virtual

> See All Events

JOB OPPORTUNITIES

Postdoctoral Fellow – Prostate Cancer Biology

University of Maryland, Baltimore – Baltimore, Maryland, United States

Associate Professor – Prostate Disease Research

Uniformed Services University of the Health Sciences – Bethesda, Maryland, United States

Postdoctoral Fellow – Prostate Cancer Research

The Vita-Salute San Raffaele University – Milan, Italy

Postdoctoral Position – Cancer Biology

Berlin School of Integrative Oncology Charité – Berlin, Germany

Postdoctoral Position – Epigenetic Control of Cancer Stem Cell Biology

University of Freiburg – Freiburg, Germany

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Prostate Cell News Twitter